Scleroderma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressors, ERA, CCBs, PA), By Indication (Systemic, Localized), By Region (North America, Europe), And Segment Forecasts, 2019 - 2026

Published: Jul, 2019 | Pages: 70 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global scleroderma therapeutics market size is expected to reach over USD 2.6 billion by 2026 registering a CAGR of 6.0%, according to a new study by Grand View Research, Inc. The market growth is credited to the availability of various therapies used off-label, such as small molecule therapies including branded, generics, and OTC drugs.

The mix of several indications and drug classes engenders a fragmented market with multiple players. Roche is the dominant company with biologic immunosuppressants, Actemra/RoActemra, Cellcept, and Rituxan contributing majorly to the company's share. Pfizer and Eli Lilly are the key companies in the market. Over the forecast period, new entrants including Boehringer Ingelheim, Corbus Pharmaceuticals, and Fibrocell will marginally displace the share of established firms in this market.

The on-label market is in the development phase. Supplemental indication approval is one of the most common strategies adopted by market participants. For example, riociguat by Bayer was previously used for PAH and currently, it is under clinical trials for the treatment of SSc-related digital ulcers. There are several other pharmaceutical companies following suit as this strategy favors the pharmaceutical industry in offsetting high development costs and in reaping larger benefits from one molecule already developed and present in the market.

Further key findings from the study suggest:

• The immunosuppressants segment held the largest market share in 2018 and is likely to maintain the dominance throughout the forecast years

• High preference for immunosuppressants owing to the favorable reimbursement scenario associated with this drug class supports its dominant market share

• Systemic scleroderma indication segment accounted for the major market share and will expand further due to use of high-priced immunosuppressants

• U.S. held the majority of the share in 2018. Expected label expansions and expected launch of first-in-class therapies coupled with an evolving reimbursement landscape for orphan drugs support continual scleroderma therapeutics market growth

• Europe trails with a lower share as compared to the U.S. majorly due to higher use of generics and biosimilars for off-label treatment of scleroderma

• Some of the key companies are F. Hoffman La-Roche Ltd.; Bristol-Myers Squibb Company; Celgene Corp.; arGentis Pharmaceuticals, LLC; Bayer AG; Boehringer Ingelheim International GmbH; Akashi Therapeutics; Prometic Life Sciences, Inc.; Emerald Health Pharmaceuticals; Kadmon Holdings, Inc.; Seattle Genetics, Inc.; Cytori Therapeutics, Inc.; Fibrocell Science, Inc.; Chemomab; Corbus Pharmaceuticals Holdings, Inc.; and Genkyotex SA

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market segmentation & scope
1.2. Market definition
1.3. Information procurement
1.3.1. Purchased database
1.3.2. GVR's internal database
1.3.3. Secondary sources & third party perspectives
1.3.4. Primary research
1.4. Information analysis
1.4.1. Data analysis models
1.5. Market formulation & data visualization
1.6. Data validation & publishing
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
2.4. Market Summary
Chapter 3. Scleroderma Therapeutics Market Variables, Trends & Scope
3.1. Scleroderma Therapeutics Market Lineage outlook
3.1.1. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Lack of curative therapies attract new players
3.3.1.2. Growing prevalence of scleroderma therapeutics
3.3.1.3. Developed regions present major opportunity markets
3.3.1.4. Expanding pharmaceutical pipeline
3.3.2. Market Restraint Analysis
3.3.2.1. Lack of well-defined regulatory and reimbursement framework impedes growth in developing regions
3.3.2.2. Reimbursement uncertainties in developed regions pose obstacles
3.4. Scleroderma Therapeutics Market Analysis Tools
3.4.1. Industry Analysis - Porter's
3.4.1.1. Supplier Power: Moderate due to the presence of many suppliers
3.4.1.2. Buyer Power: Moderate owing to the presence of providers
3.4.1.3. Substitution Threat: Low owing to no substitutes
3.4.1.4. Threat from new entrant: Moderate due to high buyer switching cost
3.4.1.5. Competitive rivalry: High due to the presence of a large number of generic manufacturers
3.4.2. PESTEL Analysis
3.4.2.1. Political Landscape
3.4.2.2. Environmental Landscape
3.4.2.3. Social Landscape
3.4.2.4. Technology Landscape
3.4.2.5. Legal Landscape
Chapter 4. Scleroderma Therapeutics Market: Drug Class Estimates & Trend Analysis
4.1. Definitions & Scope
4.2. Drug Class market share analysis, 2018 & 2026
4.3. Drug Class Dashboard
4.4. Global Scleroderma Therapeutics market, by Drug Class, 2014 to 2026
4.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
4.5.1. Immunosuppressors
4.5.1.1. Immunosuppressors Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
4.5.2. Phosphodiesterase 5 inhibitors - PHA
4.5.2.1. Phosphodiesterase 5 inhibitors - PHA Market, 2014 - 2026 (USD Million)
4.5.3. Endothelin Receptor Antagonists
4.5.3.1. Endothelin Receptor Antagonists Market, 2014 - 2026 (USD Million)
4.5.4. Prostacyclin Analogues
4.5.4.1. Prostacyclin Analogues Market, 2014 - 2026 (USD Million)
4.5.5. Calcium Channel Blockers
4.5.5.1. Calcium Channel Blockers Market, 2014 - 2026 (USD Million)
4.5.6. Analgesics
4.5.6.1. Analgesics Market, 2014 - 2026 (USD Million)
4.5.7. Others
4.5.7.1. Others Market, 2014 - 2026 (USD Million)
Chapter 5. Scleroderma Therapeutics Market: Indication Estimates & Trend Analysis
5.1. Definitions & Scope
5.2. Indication Market Share Analysis, 2018 & 2026
5.3. Indication Dashboard
5.4. Global Scleroderma Therapeutics Market, By Route of Administration, 2014 to 2026
5.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
5.5.1. Systemic
5.5.1.1. Systemic Market, 2014 - 2026 (USD Million)
5.5.2. Localized
5.5.2.1. Localized Market, 2014 - 2026 (USD Million)
Chapter 6. Scleroderma Therapeutics Market: Regional Estimates & Trend analysis, by Drug Class, and Indication
6.1. Regional Market Snapshot
6.2. Regional Market Share and Leading Players, 2018
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East & Africa
6.3. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East & Africa
6.4. Market Size, & Forecasts, and Trend Analysis, 2018 to 2026:
6.4.1. North America
6.4.1.1. North America Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.1.2. U.S.
6.4.1.2.1. U.S. Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.1.3. Canada
6.4.1.3.1. Canada Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.2. Europe
6.4.2.1. Europe Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.2.2. U.K.
6.4.2.2.1. U.K. Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.2.3. Germany
6.4.2.3.1. Germany Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.2.4. Spain
6.4.2.4.1. Spain Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.2.5. France
6.4.2.5.1. France Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.2.6. Italy
6.4.2.6.1. Italy Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.3. Asia Pacific
6.4.3.1. Asia Pacific Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.3.2. China
6.4.3.2.1. China Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.3.3. Japan
6.4.3.3.1. Japan Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.3.4. India
6.4.3.4.1. India Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.3.5. Hong Kong
6.4.3.5.1. Hong Kong Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.3.6. Singapore
6.4.3.6.1. Singapore Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.3.7. Australia
6.4.3.7.1. Australia Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.3.8. South Korea
6.4.3.8.1. South Korea Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.4. Latin America
6.4.4.1. Latin America Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.4.2. Brazil
6.4.4.2.1. Brazil Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.4.3. Mexico
6.4.4.3.1. Mexico Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.4.4. Argentina
6.4.4.4.1. Argentina Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.5. Middle East Africa
6.4.5.1. MEA Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.5.2. South Africa
6.4.5.2.1. South Africa Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.5.3. Saudi Arabia
6.4.5.3.1. Saudi Arabia Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.5.4. UAE
6.4.5.4.1. UAE Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
6.4.5.5. Qatar
6.4.5.5.1. Qatar Scleroderma Therapeutics Market, 2014 - 2026 (USD Million)
Chapter 7. Company Profiles
7.1. Recent developments & impact analysis, by key market participants
7.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
7.3. Public Companies
7.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
7.3.2. Competitive Dashboard Analysis
7.3.3. Market Differentiators
7.4. Private Companies
7.4.1. Regional network map
7.5. Company Profiles
7.5.1. F. Hoffman La Roche
7.5.1.1. Company Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Boehringer Ingelheim International GmbH
7.5.2.1. Company Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Bristol-Myers Squibb Company
7.5.3.1. Company Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. CELGENE CORPORATION
7.5.4.1. Company Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. arGentis Pharmaceuticals, Llc
7.5.5.1. Company Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Prometic Life Sciences Inc.
7.5.6.1. Company Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Akashi Therapeutics
7.5.7.1. Company Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Kadmon Holdings, Inc.
7.5.8.1. Company Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Emerald Health Pharmaceuticals
7.5.9.1. Company Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. Cytori Therapeutics Inc.
7.5.10.1. Company Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
7.5.11. Fibrocell Science, Inc.
7.5.11.1. Company Overview
7.5.11.2. Financial Performance
7.5.11.3. Product Benchmarking
7.5.11.4. Strategic Initiatives
7.5.12. Chemomab
7.5.12.1. Company Overview
7.5.12.2. Financial Performance
7.5.12.3. Product Benchmarking
7.5.12.4. Strategic Initiatives
7.5.13. Corbus Pharmaceuticals Holdings, Inc.
7.5.13.1. Company Overview
7.5.13.2. Financial Performance
7.5.13.3. Product Benchmarking
7.5.13.4. Strategic Initiatives
7.5.14. Genkyotex
7.5.14.1. Company Overview
7.5.14.2. Financial Performance
7.5.14.3. Product Benchmarking
7.5.14.4. Strategic Initiatives
7.5.15. Bayer Ag
7.5.15.1. Company Overview
7.5.15.2. Financial Performance
7.5.15.3. Product Benchmarking
7.5.15.4. Strategic Initiatives
7.5.16. Seattle Genetics, Inc.
7.5.16.1. Company Overview
7.5.16.2. Financial Performance
7.5.16.3. Product Benchmarking
7.5.16.4. Strategic Initiatives

List of Tables

TABLE 1 List of abbreviation
TABLE 2 North America scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 3 North America scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 4 U.S. scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 5 U.S. scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 6 Canada scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 7 Canada scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 8 Europe scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 9 Europe scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 10 U.K. scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 11 U.K. scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 12 Germany scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 13 Germany scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 14 Italy scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 15 Italy scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 16 France scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 17 France scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 18 Spain scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 19 Spain scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 20 Asia Pacific scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 21 Asia Pacific scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 22 Japan scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 23 Japan scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 24 China scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 25 China scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 26 India scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 27 India scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 28 Australia scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 29 Australia scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 30 South Korea scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 31 South Korea scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 32 Hongkong scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 33 Hongkong scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 34 Latin America scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 35 Latin America scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 36 Brazil scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 37 Brazil scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 38 Mexico scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 39 Mexico scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 40 Argentina scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 41 Argentina scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 42 MEA scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 43 MEA scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 44 South Africa scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 45 South Africa scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 46 Saudi Arabia scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 47 Saudi Arabia scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 48 UAE scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 49 UAE scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)
TABLE 50 Qatar scleroderma therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 51 Qatar scleroderma therapeutics market, by indication, 2014 - 2026 (USD Million)

List of Figures

Fig. 1 Scleroderma treatment market snapshot
Fig. 2 Scleroderma treatment market segmentation
Fig. 3 Scleroderma treatment market driver impact
Fig. 4 Scleroderma treatment market restraint impact
Fig. 5 Penetration & growth prospect mapping
Fig. 6 SWOT Analysis, By Factor (Political & Legal Economic and Technological)
Fig. 7 Scleroderma Treatment Market: Company Market Share (%), 2018 & 2026
Fig. 8 Scleroderma Treatment Market: Drug Classes Outlook And Key Takeaways
Fig. 9 Scleroderma Treatment Market: Drug Class Movement Analysis
Fig. 10 Immunosuppressants market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 11 ACE Inhibitors market estimates and forecast, 2015 - 2027 (USD Million)
Fig. 12 Corticosteroids market estimates and forecast, 2015 - 2027 (USD Million)
Fig. 13 Endothelin Receptor Antagonists market estimates and forecast, 2015 - 2027 (USD Million)
Fig. 14 Prostacyclin Analogues market estimates and forecast, 2015 - 2027 (USD Million)
Fig. 15 Calcium Channel Blockers market estimates and forecast, 2015 - 2027 (USD Million)
Fig. 16 PDE-5 Inhibitors market estimates and forecast, 2015 - 2027 (USD Million)
Fig. 17 Scleroderma Treatment Market Indication Outlook and Key Takeaways
Fig. 18 Scleroderma Treatment Market: Indication Movement Analysis
Fig. 19 Localized scleroderma market estimates and forecast, 2015 - 2027 (USD Million)
Fig. 20 Systemic scleroderma market estimates and forecast, 2015 - 2027 (USD Million)
Fig. 21 Scleroderma Treatment Market: Regional Outlook and Key Takeaways
Fig. 22 Scleroderma Treatment Market: Regional Movement Analysis
Fig. 23 North America scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 24 U.S. scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 25 Canada scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 26 Europe scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 27 Germany scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 28 U.K. scleroderma treatment market, 2014 - 2026 (USD Million)
Fig. 29 France scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 30 Italy scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 31 Spain scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 32 Asia-Pacific scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 33 Japan scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 34 Hong Kong scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 35 Singapore scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 36 China scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 37 India scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 38 Australia scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 39 South Korea scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 40 Latin America scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 41 Brazil scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 42 Mexico scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 43 Argentina scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 44 Middle East scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 45 Saudi Arabia scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 46 UAE scleroderma treatment Market Estimates and Forecast, 2014 - 2026 (USD Million)
Fig. 47 Qatar scleroderma treatment market estimates and forecast, 2014 - 2026 (USD Million)
Fig. 48 Strategic Framework